Patient-Reported Outcomes to Evaluate Three Pharmaceutical Grade Medicinal Cannabis Oils in Patients with Chronic Pain of Musculoskeletal Origi
- Conditions
- Chronic pain of musculoskeletal originMusculoskeletal - OsteoarthritisMusculoskeletal - Other muscular and skeletal disordersInflammatory and Immune System - Rheumatoid arthritisAnaesthesiology - Pain management
- Registration Number
- ACTRN12622000750785
- Lead Sponsor
- evin Health Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
•Aged over 18 years
•A diagnosis of treatment resistant chronic pain of musculoskeletal origin
•Ability to give informed consent
•Willing and able to follow study instructions and likely to complete all PROM requirements via study website
•Able to provide informed consent
•Have a life-expectancy of >3 months
•Understand that there is a risk of prosecution if driving a car while under treatment
•Patient has been identified as eligible to receive medicinal cannabis under the TGA Special Access Scheme/Authorised by the Principal Investigator for chronic pain
•Participants must have been lawfully prescribed Levin Balance, Levin CBD+ or Levin THC+ by the Principal Investigator
•Participants agree to abstain from using another cannabis product other than their Levin Health product for the duration of their enrolment in the study
•have cognitive impairment
•are pregnant
•are unable to speak, read and/or write in English
•are unable to provide informed consent
•are unable to provide an email address
•have received prescription medicinal cannabis within the last 4 weeks
•are using illicit cannabis
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method